PET myocardial perfusion quantification: anatomy of a spreading functional technique

Juárez-Orozco, Luis Eduardo; Cruz-Mendoza, José Raúl; Guinto-Nishimura, Gerardo Yoshiaki; Walls-Laguarda, Lourdes; Casares-Echeverría, L. J.; Meave-González, Aloha; Knuuti, Juhani; Alexánderson, Erick

doi:10.1007/s40336-018-0263-1

Cited by 9 publications

(8 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET is currently used as a standard in cardiology for myocardial perfusion evaluation (16,(32)(33)(34)(35). Therefore, the new functionality of PET devices that enables positronium imaging, simultaneously with standard SUV imaging, shall constitute a natural enhancement of the diagnosis by preserving the current PET imaging protocol.…”

Section: Discussionmentioning

confidence: 99%

“…PET is used as standard in cardiovascular imaging, for example, for semi-quantitative myocardial perfusion evaluation (32,33). For research an assessment of atherosclerosis (16,34) or the diagnosis and risk stratification in patients with known or suspected coronary artery disease (32,35) Nevertheless, standard PET does not reveal the tissue histology and fails to determine if the organic cause of the detected disorder is cancer origin, inflammation, or intracardiac thrombus.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Developing a Novel Positronium Biomarker for Cardiac Myxoma Imaging

Moskal

Kubicz

Grudzień

et al. 2021

Preprint

View full text Add to dashboard Cite

Here, positronium imaging is presented to determine cardiac myxoma (CM) extracted from patients undergoing urgent cardiac surgery due to unexpected atrial masses. Positronium is an atom build from an electron and a positron, produced copiously in intra-molecular voids during the PET imaging. CM, the most common cardiac tumor in adults, accounts for 50-75% of benign cardiac tumors. We aimed to assess if positronium serves as a biomarker for diagnosing CM. Perioperative examinations and histopathology staining in six patients confirmed the primary diagnosis of CM. We observed significant differences in the mean positronium lifetime between tumor and normal tissues, with an average value of 1.92(02) ns and 2.72(05) ns for CM and the adipose tissue, respectively. Our findings, combined with positronium lifetime imaging, reveals the novel emerging positronium biomarker for cardiovascular imaging.One-Sentence SummaryPositronium may serve as an imaging biomarker for cancer diagnostics.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Developing a Novel Positronium Biomarker for Cardiac Myxoma Imaging

Moskal

Kubicz

Grudzień

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The activity injected depends on the equipment for scanning (2D=370MBq, 3D=555mBq). Contemporary, PET scanners operate in 3D acquisition mode, therefore 13 (17). Also, an abnormal global MFR <2.0 was found to be independently associated with a higher annual event rate for major adverse cardiac events and cardiac death over provided incremental information to the conventional stress 13 N-ammonia perfusion PET study for predicting an adverse outcome.…”

Section: Pharmacokinetic Parameters Of 13 N-ammoniamentioning

confidence: 93%

PET/CT with <sup>13</sup>N-ammonia

Carvajal-Juárez¹,

Monroy-Gonzalez

Espínola‐Zavaleta³

et al. 2019

Annals of Nuclear Cardiology

View full text Add to dashboard Cite

Currently, 13 N-ammonia and Rubidium-82 (82 Rb) are the only FDA-approved myocardial perfusion positron emission tomography (PET) tracers for myocardial perfusion imaging in the evaluation of suspected or known coronary artery disease (CAD), quantification of left ventricular volumes and systolic function and quantification of global and regional myocardial blood flow (MBF) and myocardial flow reserve (MFR). Nevertheless, there are physical, chemical and molecular differences between them. The ideal perfusion tracer would include 100% extraction from blood to tissue, and 100% retention, resulting in a linear relationship between MBF and the measured tracer activity over a wide range. However, both 13 N-ammonia and 82 Rb have limited characteristics. In this review, we aim to analyze 13 N-ammonia in detail, and its differences with other radiotracers for the assessment of myocardial perfusion.

show abstract

“…Notably, the intrinsic advantages of PET, including its wide range of physiological radiotracers available and its full quantitative capabilities, set the ground for the value addition to the phase analysis of ventricular synchrony in establishing the so-called “one-stop shop”15 in which perfusion or viability, scar location, and extent, ventricular volumes, and function (both systolic and diastolic), and synchrony36 can be simultaneously evaluated. Moreover, comprehensive imaging can be boosted through the utilization of currently available hybrid equipment (PET/CT and PET/MR) that allows for complementary anatomic information (e.g., epicardial fat, calcium score, and venous system structure) to be obtained within the same imaging session.…”

Section: Reference Valuesmentioning

confidence: 99%

Phase analysis of gated PET in the evaluation of mechanical ventricular synchrony: A narrative overview

Juárez-Orozco

Monroy-Gonzalez

Prakken

et al. 2019

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

Noninvasive imaging modalities offer the possibility to dynamically evaluate cardiac motion during the cardiac cycle by means of ECG-gated acquisitions. Such motion characterization along with orientation, segmentation preprocessing, and ultimately, phase analysis, can provide quantitative estimates of ventricular mechanical synchrony. Current evidence on the role of mechanical synchrony evaluation is mainly available for echocardiography and gated single-photon emission computed tomography, but less is known about the utilization of gated positron emission tomography (PET). Although data available are sparse, there is indication that mechanical synchrony evaluation can be of diagnostic and prognostic values in patients with known or suspected coronary artery disease-related myocardial ischemia, prediction of response to cardiac resynchronization therapy, and estimation of risk for adverse cardiac events in patients’ heart failure. As such, the evaluation of mechanical ventricular synchrony through phase analysis of gated acquisitions represents a value addition to modern cardiac PET imaging modality, which warrants further research and development in the evaluation of patients with cardiovascular disease.Electronic supplementary materialThe online version of this article (10.1007/s12350-019-01670-7) contains supplementary material, which is available to authorized users.

show abstract

PET myocardial perfusion quantification: anatomy of a spreading functional technique

Cited by 9 publications

References 63 publications

Developing a Novel Positronium Biomarker for Cardiac Myxoma Imaging

Developing a Novel Positronium Biomarker for Cardiac Myxoma Imaging

PET/CT with <sup>13</sup>N-ammonia

Phase analysis of gated PET in the evaluation of mechanical ventricular synchrony: A narrative overview

Contact Info

Product

Resources

About